Русский
Patient with cerebral microangiopathy
DOI: https://dx.doi.org/10.18565/pharmateca.2024.9.78-86
Kamchatnov P.R., Cheremin R.A., Prikazchikov S.V., Skipetrova L.A., Chugunov A.V.
1) Pirogov Russian National Research Medical University, Moscow, Russia; 2) Buyanov City Clinical Hospital of the Moscow Healthcare Department, Moscow, Russia; 3) Center for Speech Pathology and Neurorehabilitation of the Moscow Healthcare Department, Moscow, Russia; 4) Research Institute of Healthcare Organization and Medical Management of the Moscow Healthcare Department, Moscow, Russia
Cerebral microangiopathy (CMA) is a common cause of cognitive, mental and behavioral disorders. In addition to direct ischemic and hemorrhagic damage to the nervous system, systemic inflammation, neuroinflammation, and neurodegeneration take part in the pathogenesis of CMA. The complexity of the pathogenesis of the disease necessitates combination therapy that can affect various pathogenetic mechanisms. The drug of choice for patients in this category is a nootropic agent containing proteins and polypeptides from the brain of pig embryos, the effectiveness and safety of which have been repeatedly demonstrated both in randomized clinical trials and in real clinical practice. The possibility of using this drug in patients with CMA is illustrated by two clinical case reports.
Keywords: cerebral microangiopathy, neurodegeneration, chronic cerebral ischemia, neuroinflammation, neuroprotection
About the Autors
Corresponding author: Pavel R. Kamchatnov, Dr. Sci. (Med.), Professor, Department of Neurology, Neurosurgery and Medical Genetics, Faculty of Physics, Pirogov Russian National Research Medical University; Buyanov City Clinical Hospital of the Moscow Healthcare Department, Moscow, Russia; pavkam7@gmail.com
Similar Articles
